Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
2019 · Molecular Cancer · 1,145 citations
https://doi.org/10.1186/s12943-019-1091-2
S
Suxia Luo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
165
Papers
6.6K
Citations
34
h-index
65
i10-index
Suxia Luo is an academic researcher from Guangzhou University of Chinese Medicine. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Cancer Immunotherapy and Biomarkers & Esophageal Cancer Research and Treatment. The author has an h-index of 34, co-authored 141 publications.
ORCID: 0000-0002-8639-7314Papers by this author
worksRegulation of PD-L1 expression in the tumor microenvironment
2021 · Journal of Hematology & Oncology · 615 citations
https://doi.org/10.1186/s13045-020-01027-5
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
2021 · Journal of Hematology & Oncology · 239 citations
https://doi.org/10.1186/s13045-021-01045-x
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study
2021 · Biomarker Research · 177 citations
https://doi.org/10.1186/s40364-021-00310-y
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
2022 · BMC Medicine · 73 citations
https://doi.org/10.1186/s12916-022-02605-9
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia
2021 · ESMO Open · 50 citations
https://doi.org/10.1016/j.esmoop.2021.100341
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat